Piper Sandler analyst Matt O’Brien raised the firm’s price target on Stryker to $360 from $310 and keeps an Overweight rating on the shares. The firm anticipates some concern around the political backdrop here in the U.S., but doubts med tech will be pressured regardless of who wins the Presidency. However, volumes and pricing for 2024 should be good across the sector. Piper sees little GLP related risk for the full year and anticipates 2024 will be a good year for med tech stocks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK:
- Stryker price target raised to $345 from $315 at RBC Capital
- Stryker sees 1st case using Blueprint MR system in Europe in February
- Stryker announces 2023 sales surpassed $20B
- Stryker announces 2023 sales surpassed $20 billion
- Stryker to announce financial results for its fourth quarter and full year 2023